Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Merck & Co., Inc. (MRK) Price & Performance

Teucrium Corn FundTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Merck & Co., Inc. — how do they compare? Teucrium Corn Fund trades at $17.69, while Merck & Co., Inc. trades at $130.26 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while Teucrium Corn Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.

CORNMRK
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$19.12$131.84
52-Week Low
$16.46$77.60
Market Cap
$323.00B
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.

The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.

Merck & Co., Inc.

Merck (MRK) trades at $130.45, up 1.46% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, though the P/E ratio of 104.74 reflects high valuation expectations. Recent acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while dividend payments of $0.85 per share provide income stability.

Outlook remains positive with a consensus price target of $139.90, implying 7.2% upside, supported by 67.6% analyst buy ratings. Key risks include integration challenges from acquisitions, patent expirations, and regulatory pressures. Earnings growth and pipeline advancements are critical for sustaining the current premium valuation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK